Your session is about to expire
← Back to Search
[18F]FluorThanatrace PET/CT Imaging for Ovarian Cancer
Phase 1
Recruiting
Led By Fiona Simpkins, MD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants will be ≥ 18 years of age
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Study Summary
This trial is testing a new imaging technique to see how well it works in women with ovarian cancer.
Who is the study for?
This trial is for women aged 18 or older with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer. They must have at least one lesion that's visible on standard imaging and can be either newly diagnosed or have recurrent cancer. Pregnant or breastfeeding women and those unable to tolerate imaging procedures are excluded.Check my eligibility
What is being tested?
[18F]FluorThanatrace (FTT) is being tested in this study using PET/CT scans to understand its distribution, metabolism, and excretion in patients with gynecological cancers. The trial has two parts: a Biodistribution cohort for dosimetry calculations and a Dynamic cohort to assess FTT uptake compared to PARP-1 activity in tissues.See study design
What are the potential side effects?
As the intervention involves diagnostic imaging rather than treatment drugs, side effects may include discomfort from lying still during the PET/CT scan and exposure to radiation typical of such medical imaging procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Adverse Events
Trial Design
2Treatment groups
Experimental Treatment
Group I: DynamicExperimental Treatment2 Interventions
The Dynamic cohort will include up to 36 patients who will undergo 1 static skull base to mid-thigh scans imaging post injection of [18F]FTT.
Group II: BiodistributionExperimental Treatment2 Interventions
The Biodistribution cohort will include up to 4 patients who will undergo a series of vertex to mid-thigh biodistribution [18F]FTT PET/CT scans over a period of approximately 4 hours.
Up to 10 subjects were initially planned for this cohort, however, the first 4 subjects have been enrolled and initial data analysis for these completed. The decision was made to close enrollment for this cohort as we do not believe that we need to complete the up to 10 subjects originally planned for this cohort as the initial data shows consistent and repeatable data that we do not believe would change significantly with the addition of 6 more subjects.
Find a Location
Who is running the clinical trial?
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,029 Total Patients Enrolled
9 Trials studying Ovarian Cancer
961 Patients Enrolled for Ovarian Cancer
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,629 Total Patients Enrolled
9 Trials studying Ovarian Cancer
961 Patients Enrolled for Ovarian Cancer
Fiona Simpkins, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine
2 Previous Clinical Trials
92 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have or had ovarian, fallopian tube, or peritoneal cancer.I am 18 years old or older.My doctor thinks I have a health issue that could make participating in the study unsafe for me.
Research Study Groups:
This trial has the following groups:- Group 1: Biodistribution
- Group 2: Dynamic
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are researchers presently seeking out participants for this trial?
"Affirmative. As indicated by the clinicaltrials.gov database, this research venture is presently searching for recruits; it was initially posted on January 14th 2016 and updated lastly November 7th 2022. 35 participants are required across one medical site."
Answered by AI
How many participants have been accepted into this clinical experiment?
"Affirmative, the information hosted on clinicaltrials.gov verifies that this experiment is currently recruiting participants. It was posted on January 14th 2016 and last revised on November 7th 2022; seeking 35 volunteers at a single medical centre."
Answered by AI
Has the FDA granted permission for [18F]FluorThanatrace to be used in treatments?
"Our team at Power believes [18F]FluorThanatrace to be a moderately safe compound, scoring it a 1 out of 3. This is because this Phase 1 trial does not have as much information supporting its safety and efficacy yet."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger